Status: Recruiting
Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL
Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive lymphoma. At present, the treatment of new diagnosed AITL has limited efficacy and a high recurrence rate. The study seeks to explore the possibility of improving the efficacy of immunotherapy and chemotherapy and epigenetically regulated drugs.
Participants needed: 40
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: The Affiliated Hospital of Xuzhou Medical UniversityUpdated: Sep 11, 2025Locations: 1
Eligibility criteria
Pathological diagnosis of AITL according to WHO classification in 2016, and path... [+4]
Patients with abnormal liver and kidney function, specifically serum direct bili... [+13]